AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): A method of raising HDL level and increasing HDL anti-inflammatory activity ~~antiameliorating one or more symptoms of atherosclerosis~~ in a mammal, said method comprising administering to said mammal a phospholipid in an amount sufficient to increase HDL level in said mammal, ~~ameliorate one or more symptoms of atherosclerosis,~~wherein said phospholipid is a synthetic phospholipid selected from the group consisting of phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, and phosphatidyl inositol, having fatty acids in the *sn-1* and *sn-2* positions that are the same and that range in length from 3 to 24 carbons.

Claim 2 (Original): The method of claim 1, wherein said phospholipid is a phospholipid that inhibits upregulation of an MKP-1 gene,

Claim 3 (Currently Amended): The method of claim 1, wherein said phospholipid is a ~~phospholipid selected from the group consisting of~~ phosphatidyl choline~~, phosphatidyl serine, phosphatidyl ethanolamine, and phosphatidyl inositol, and said phospholipid comprises independently selected fatty acids in the *sn* 1 and *sn* 2 positions ranging in length from about 4 to about 24 carbons~~.

Claim 4 (Currently Amended): The method of ~~claim~~ 31, wherein the fatty acids in ~~in~~ the *sn*-1 and *sn*-2 positions are ~~independently~~ selected from the group consisting of propionoyl, butanoyl, pentanoyl, caproyl, heptanoyl, capryloyl, nonanoyl, capryl, undcanoyl, lauroyl, tridecanoyl, and myristoyl.

Claim 5 (Original): The method of claim 1, wherein said phospholipid is 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine or an analogue thereof,

Claim 6 (Original): The method of claim 1, wherein said phospholipid is provided in a unit dosage form,

Claim 7 (Original): The method of claim 1, wherein said phospholipid is provided in a combination of phospholipids,

Claim 8 (Original): The method of claim 1, where said administration is by a route selected from the group consisting of oral administration, nasal administration, rectal administration, intraperitoneal injection, and intravascular injection, subcutaneous injection, transcutaneous administration, and intramuscular injection,

Claim 9 (Original): The method of claim 1, wherein said administration is oral administration,

Claim 10 (Original): The method of claim 1, wherein said administration is an injection,

Claim 11 (Original): The method of claim 1, wherein said symptoms are in a human patient diagnosed as having or at risk for atherosclerosis,

Claim 12 (Original): The method of claim 1, wherein said symptoms are in a human patient diagnosed as having atherosclerosis,

Claim 13 (Currently amended): A method of mitigating or preventing a coronary complication associated with an acute phase response to an inflammation in a mammal, wherein said coronary complication is a symptom of atherosclerosis, said method comprising administering to a mammal having said acute phase response, or at risk for said acute phase response, a phospholipid <u>according to any of claims 1-6</u> in an amount sufficient to mitigate or prevent said coronary complication,

Claim 14-81 (Canceled).